CYP19A1 and breast carcinoma: The Breast International Group (BIG) trial 1–98 was a phase III randomized clinical trial that evaluated letrozole (an aromatase inhibitor) versus tamoxifen (a SERM) as an adjuvant therapy for early stage hormone receptor-positive breast cancer among 8010 postmenopausal women [15].